You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

FC(PO)+R

Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)      Intent: Palliative
Regimen Category: Evidence-informed
Drugs Used:
riTUXimab,
fludarabine,
cyclophosphamide,
riTUXimab (subcut)
... Show more tags
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia
ODB Limited Use
    fludarabine - For the first-line treatment of CLL in combination with rituximab (tablets; with or without cyclophosphamide)
ODB Limited Use
    fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia
... Show more tags

Regimen Monograph

Aug 2020
Table of Contents
Pre-Printed Order
pdf download FC-PO R Leukemia pdf download FC-PO R Lymphoma

Patient Info Sheet

Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.

You might also be interested in

ALEM; ALEM(IV)

FC

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration